REGN-COV2 Independent Data Monitoring Committee Recommends Holding Enrollment in Hospitalized Patients with High Oxygen Requirements and Continuing Enrollment in Patients with Low or No Oxygen Requirements
The Pharma Data
OCTOBER 30, 2020
About the REGN-COV2 Trial in Hospitalized Patients. About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. Cohort 1A: patients not requiring oxygen. Cohort 2: patients on high-flow oxygen.
Let's personalize your content